Saliogen Therapeutics Closes $115 Million Oversubscribed Series B Financing To Advance Gene Coding™ – A New Category Of Genetic Medicine
Saliogen Therapeutics Closes $115 Million Oversubscribed Series B Financing To Advance Gene Coding™ – A New Category Of Genetic Medicine
01/05/22, 8:00 AM
Location
cambridge
Money raised
$115 million
Round Type
series b
SalioGen Therapeutics, a privately held biotechnology company developing Gene CodingTM, a new category of genetic medicine, today announced the completion of an oversubscribed and up-sized $115 million Series B financing.